Hyloris PharmaceuticalsLTS:0AB6 +0.22%64 Days Payable is 2,399.04 as of Dec. 2025, which is 67% below its 10-year median of 7,192.55. GuruFocus rates LTS:0AB6 with a GF Score™ of 64/100 and a GF Value™ of €9.53 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 702 Biotechnology companies, Hyloris Pharmaceuticals ranks better than 92.02% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0AB6 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Hyloris Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hyloris Pharmaceuticals Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Hyloris Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Hyloris Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hyloris Pharmaceuticals (LTS:0AB6) has a Days Payable of 2,399.04 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Hyloris Pharmaceuticals and its competitors. This is 67% below median its historical median of 7,192.55. Over the past decade, Hyloris Pharmaceuticals' Days Payable has ranged from 3,134.76 to 13,610.08. According to the industry distribution chart, Hyloris Pharmaceuticals ranks #56 out of 702 companies in the Biotechnology industry, placing it in the top 8%.
Is Hyloris Pharmaceuticals' Days Payable too high?
Hyloris Pharmaceuticals' current Days Payable of 2,399.04 is 67% below median its 10-year median of 7,192.55. Over the past 10 years, this metric has ranged from a low of 3,134.76 to a high of 13,610.08. The Biotechnology industry median Days Payable is 113.56. Hyloris Pharmaceuticals' value of 2,399.04 is 2012.6% above this industry median. Based on the distribution chart, Hyloris Pharmaceuticals ranks #56 out of 702 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Hyloris Pharmaceuticals has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hyloris Pharmaceuticals' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hyloris Pharmaceuticals ranks #56 out of 702 companies for Days Payable. This places Hyloris Pharmaceuticals in the top 8% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.56. Hyloris Pharmaceuticals' value of 2,399.04 is 2012.6% above this benchmark. Historically, Hyloris Pharmaceuticals' own Days Payable has ranged from 3,134.76 to 13,610.08 over the past decade. While the company's 10-year median is 7,192.55 vs. the industry median of 113.56, Hyloris Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hyloris Pharmaceuticals's current Days Payable of 2,399.04 is 2012.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Hyloris Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hyloris Pharmaceuticals's current Days Payable is 2,399.04, which is 67% below median its own 10-year median of 7,192.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hyloris Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hyloris Pharmaceuticals (LTS:0AB6) is currently considered Possible Value Trap. The stock's GF Value™ is €9.53, compared to a current price of €4.49 — trading 52.9% below its estimated fair value. The current Days Payable is 2,399.04, which is 67% below median its 10-year median of 7,192.55 and 2012.6% above the Biotechnology industry median of 113.56. Hyloris Pharmaceuticals' overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Hyloris Pharmaceuticals (LTS:0AB6), the current Days Payable is 2,399.04 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hyloris Pharmaceuticals (LTS:0AB6) Overvalued in 2026?
Based on GuruFocus' analysis, Hyloris Pharmaceuticals stock appears to be undervalued.
The current stock price of €4.49 is trading 52.9% below its estimated GF Value™ of €9.53.
GuruFocus considers Hyloris Pharmaceuticals to be Possible Value Trap.
Key valuation signals for LTS:0AB6:
Days Payable: 2,399.04 (67% below median its 10-year median of 7,192.55)
GF Value™: €9.53 vs. price of €4.49 (52.9% below fair value)
Industry Position: 2012.6% above the Biotechnology median (#56 of 702)
No single metric tells the full story. See the LTS:0AB6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has three early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, Podofilox Ge, and Maxigesic IV. Its revenue is mainly generated in the United States.
64GF Score
Get the complete analysis for LTS:0AB6
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0AB6 has been successfully added to your 
